e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Pulmonary hypertension: novelties from the bench
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension
M. Connolly (London, United Kingdom), S. Wort (London, United Kingdom), B. Garfield (London, United Kingdom), A. Crosby (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), P. Kemp (London, United Kingdom)
Source:
International Congress 2019 – Pulmonary hypertension: novelties from the bench
Session:
Pulmonary hypertension: novelties from the bench
Session type:
Poster Discussion
Number:
5045
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Connolly (London, United Kingdom), S. Wort (London, United Kingdom), B. Garfield (London, United Kingdom), A. Crosby (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), P. Kemp (London, United Kingdom). MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension. 5045
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Cold exposure lowered miR-21-5p expression in monocrotaline induced pulmonary artery hypertension.
Source: International Congress 2018 – Experimental research in pulmonary hypertension
Year: 2018
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Effect of eNOS gene overexpression on the vascular reactivity of isolated pulmonary arteries of chronic hypoxic rats
Source: Annual Congress 2006 - Taormina 4th ERS Lung Science Conference "hypoxia in lung biology and disease"
Year: 2006
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Shroom expression is attenuated in pulmonary arterial hypertension
Source: Eur Respir J 2008; 32: 871-880
Year: 2008
The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
The PPAR-β/δ agonist GW0742 reverses right venticular hypertrophy in a chronically hypoxic rat model of pulmonary hypertension
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
Role of NFATc3 in chronic hypoxia induced pulmonary hypertension in neonatal mice
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Lodenafil improves hemodynamics and right ventricular remodeling in monocrotaline-induced model of pulmonary arterial hypertension in rats
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept